Pharmafile Logo
Pharmafocus logo
Advanced Search

hep C

Showing 15 posts of 44 posts found.

Sovaldi combo sees CHMP green light

September 29, 2014
Sales and Marketing CHMP, EU, Gilead, HCV, harvoni, hep C, sovaldi

The CHMP is recommending that Gilead’s new combination hepatitis C drug therapy Harvoni should be approved for use across the …

News
Sovaldi image

Gilead allows generic prices for Sovaldi

September 16, 2014
Manufacturing and Production, Sales and Marketing Gilead, hep C, hepatitis C, sofosbuvir, sovaldi

Gilead will allow Indian generic drug firms to make cheap copies of its new hepatitis C pill Sovaldi in an …

News
Incivek image

Vertex ditches its once-stellar hep C drug

August 14, 2014
Sales and Marketing Gilead, Incivek, Vertex, hep C, sovaldi

Vertex will stop selling its once-blockbuster hepatitis C drug in the US this autumn after being crushed by new therapies. …

News
sovaldi_ariad_sofosbuvir_bottle_1

NHS England’s Sovaldi fund: opening the floodgates?

July 26, 2014
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDG, NICE, Professor David Haslam, hep C, sovaldi

Whilst seemingly more and more barriers are being erected to slow down the adoption of new medicines, there is a …

Feature
Sovaldi (sofosbuvir) image

Sovaldi scores in HIV patients

July 21, 2014
Sales and Marketing Gilead, HIV, JAMA, hep C, hepatitis C, sovaldi

Patients with HIV and hepatitis C virus (HCV) have responded well to a combination of Gilead Sciences’ Sovaldi and ribavirin …

News
abbvie image

AbbVie a step closer to Shire takeover

July 14, 2014
Sales and Marketing ADHD, AbbVie, Abbott, Humira, Shire, hep C, takeover

Shire is recommending a new offer from suitor AbbVie that could finally see the US giant merge with the Dublin-based …

News
boehringer image

Boehringer abandons hep C

June 23, 2014
Research and Development, Sales and Marketing AbbVie, Boehringer, HCV, faldaprevir, german, hep C

Boehringer Ingelheim has abandoned its hepatitis C (HCV) drug development programme as a dead loss after ‘re-evaluating’ its strategy. The …

News
Abbvie image

AbbVie hep C treatment fast-tracked

June 18, 2014
Research and Development, Sales and Marketing AbbVie, Abbott, EMA, EU, Gilead, HCV, hep C, sovaldi

The European regulator is to fast-track AbbVie’s oral, interferon-free treatment for adults with chronic genotype 1 (GT1) hepatitis C virus …

News
gilead_-sciences

NICE rejection looms for Sovaldi

June 16, 2014
Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …

News
Merck image

Merck buys Idenix

June 10, 2014
Manufacturing and Production, Sales and Marketing HCV, IDX21437, IDX21459, Merck, hep C, idenix

Merck is to improve its pipeline of hepatitis C virus (HCV) treatments by splashing out $3.85 billion on biopharma firm …

News
Sovaldi image

Sovaldi hurdles first drug pricing barrier

June 10, 2014
Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi

Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …

News

Sales forecasts leave Sovaldi top and Januvia lagging

May 23, 2014
Sales and Marketing Gilead, Januvia, Merck, diabetes, ep, hep C, sovaldi

Sovaldi has topped analysts’ estimates for future growth but Merck’s big-selling diabetes drug Januvia is falling by the wayside. This …

News
merck_incweb

Merck gets hep C boost as competition ramps up

April 11, 2014
Research and Development, Sales and Marketing Merck, daclatasvir, hep C, sovaldi

Merck has released promising data from a trial which uses two of its investigational compounds to treat patients with hepatitis …

News
BMS image

BMS/AZ fat disorder drug gains FDA approval

February 26, 2014
Research and Development, Sales and Marketing AstraZeneca, BMS, FDA, hep C, metreleptin, myalept

Bristol-Myers Squibb and partner AstraZeneca have been granted FDA approval for a new drug to treat rare and potentially fatal …

News
Gilead image

‘Compassionate’ use of hep C combo

February 24, 2014
Research and Development, Sales and Marketing CHMP, EMA, Gilead, hep C, ledipasvir, sovaldi

A key adviser to the European regulator has said that Gilead Sciences’ fixed-dose combination of Sovaldi and ledipasvir can be …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024